Otsuka Pharmaceutical Company, Limited

Aichi Prefecture

Medical Biological Laboratories Co., Ltd.

Kiyotaka Kuzushima

Yoshinori Ito

Yasuo Morishima

Ayako Okamura

Yoshiki Akatsuka

The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.

Cytotoxic T-cell epitope peptides that specifically attack epstein-barr virus-infected cells and uses thereof

A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.

Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same

Growing community of inventors

Nagoya, Japan

Kiyotaka Kuzushima